Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:DWTX NASDAQ:HUMA NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.16-7.3%$2.62$0.49▼$3.62$214.08M1.57849,784 shs565,964 shsDWTXDogwood Therapeutics$1.83-7.6%$2.09$1.28▼$9.50$61.13M1.68119,906 shs114,856 shsHUMAHumacyte$0.93-7.0%$0.85$0.55▼$2.93$222.02M2.316.24 million shs7.48 million shsTNYATenaya Therapeutics$0.86-8.3%$0.78$0.39▼$2.35$202.89M2.774.97 million shs7.24 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-7.30%-9.24%-13.94%-6.09%+173.42%DWTXDogwood Therapeutics-7.58%+10.91%+7.02%-40.39%-62.27%HUMAHumacyte-6.99%-12.25%+26.36%-7.91%-50.26%TNYATenaya Therapeutics-8.31%-14.27%+11.34%+29.89%+121.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.16-7.3%$2.62$0.49▼$3.62$214.08M1.57849,784 shs565,964 shsDWTXDogwood Therapeutics$1.83-7.6%$2.09$1.28▼$9.50$61.13M1.68119,906 shs114,856 shsHUMAHumacyte$0.93-7.0%$0.85$0.55▼$2.93$222.02M2.316.24 million shs7.48 million shsTNYATenaya Therapeutics$0.86-8.3%$0.78$0.39▼$2.35$202.89M2.774.97 million shs7.24 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-7.30%-9.24%-13.94%-6.09%+173.42%DWTXDogwood Therapeutics-7.58%+10.91%+7.02%-40.39%-62.27%HUMAHumacyte-6.99%-12.25%+26.36%-7.91%-50.26%TNYATenaya Therapeutics-8.31%-14.27%+11.34%+29.89%+121.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.88Moderate Buy$6.60205.56% UpsideDWTXDogwood Therapeutics 2.00Hold$12.00555.74% UpsideHUMAHumacyte 2.75Moderate Buy$7.57714.04% UpsideTNYATenaya Therapeutics 2.86Moderate Buy$4.00366.58% UpsideCurrent Analyst Ratings BreakdownLatest DWTX, HUMA, CNTX, and TNYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.004/28/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/28/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/27/2026DWTXDogwood Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/21/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026HUMAHumacyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.003/27/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $3.003/24/2026CNTXContext Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.57 per shareN/ADWTXDogwood TherapeuticsN/AN/AN/AN/A$2.33 per shareN/AHUMAHumacyte$2.02M102.43N/AN/A$0.05 per share18.60TNYATenaya Therapeutics$225K826.81N/AN/A$0.49 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%N/ADWTXDogwood Therapeutics-$34.26M-$10.60N/AN/AN/AN/A-358.33%-30.47%N/AHUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%N/ATNYATenaya Therapeutics-$90.60M-$0.47N/AN/AN/AN/A-80.56%-65.21%N/ALatest DWTX, HUMA, CNTX, and TNYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026DWTXDogwood Therapeutics-$0.22-$0.15+$0.07-$0.15N/AN/A5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A5/6/2026Q1 2026TNYATenaya Therapeutics-$0.09-$0.09N/A-$0.09$7.50 million$0.23 million3/27/2026Q4 2025HUMAHumacyte-$0.13-$0.13N/A-$0.13$1.35 million$0.47 million3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A3/18/2026Q4 2025DWTXDogwood Therapeutics-$1.22-$0.26+$0.96-$0.26N/AN/A3/11/2026Q4 2025TNYATenaya Therapeutics-$0.12-$0.12N/A-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96DWTXDogwood TherapeuticsN/A2.762.76HUMAHumacyte5.463.932.95TNYATenaya TherapeuticsN/A5.755.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%DWTXDogwood Therapeutics9.05%HUMAHumacyte44.71%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%DWTXDogwood Therapeutics0.20%HUMAHumacyte3.10%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableDWTXDogwood Therapeutics533.40 million33.34 millionN/AHUMAHumacyte150222.02 million215.14 millionOptionableTNYATenaya Therapeutics110217.00 million111.43 millionOptionableDWTX, HUMA, CNTX, and TNYA HeadlinesRecent News About These CompaniesPositive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with ...May 15 at 12:03 AM | markets.businessinsider.comTenaya Therapeutics' gene therapy data highlights early heart rhythm improvementsMay 15 at 12:03 AM | msn.comTenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC TranscriptMay 15 at 8:04 PM | seekingalpha.comTenaya Therapeutics Reports Significant Reductions in Premature Ventricular Contractions in Interim Results from TN-401 Gene Therapy Clinical TrialMay 15 at 6:31 AM | quiverquant.comQPositive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVCMay 15 at 6:01 AM | globenewswire.comTenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?May 12, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)May 11, 2026 | theglobeandmail.comTenaya Therapeutics (NASDAQ:TNYA) Upgraded by Wall Street Zen to "Hold" RatingMay 9, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Tenaya Therapeutics (TNYA)May 7, 2026 | theglobeandmail.comTenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue EstimatesMay 6, 2026 | zacks.comTenaya Therapeutics (NASDAQ:TNYA) Posts Earnings Results, Hits EstimatesMay 6, 2026 | marketbeat.comTenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comTenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 3, 2026 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 4.4% - Here's WhyApril 30, 2026 | marketbeat.comTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...April 27, 2026 | finance.yahoo.comTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026April 27, 2026 | globenewswire.comTenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20March 27, 2026 | msn.comWilliam Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product PipelineMarch 24, 2026 | insidermonkey.comTenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensusMarch 20, 2026 | msn.comTenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam DealMarch 13, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026DWTX, HUMA, CNTX, and TNYA Company DescriptionsContext Therapeutics NASDAQ:CNTX$2.16 -0.17 (-7.30%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$2.20 +0.04 (+1.85%) As of 05/15/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Dogwood Therapeutics NASDAQ:DWTX$1.83 -0.15 (-7.58%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.84 +0.01 (+0.55%) As of 05/15/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Humacyte NASDAQ:HUMA$0.93 -0.07 (-6.99%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.95 +0.02 (+2.35%) As of 05/15/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Tenaya Therapeutics NASDAQ:TNYA$0.86 -0.08 (-8.31%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.84 -0.02 (-2.02%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
